What's Happening?
PCI Pharma Services is significantly expanding its U.S. operations as part of a $1 billion global expansion initiative. The company is investing $100 million in its San Diego campus to add a high-speed isolator filling line, which will more than double
the site's capacity for filling ready-to-use prefilled syringes and cartridges. This expansion is expected to be operational by the first half of 2028. PCI currently produces over 45 FDA-approved products at its San Diego facility, one of nine U.S. locations. The company is also enhancing its capabilities at its Bedford, New Hampshire site, with plans to open a GMP-ready isolator vial and lyophilization line capable of producing up to 33 million vials annually. This expansion comes amid disruptions in the outsourced fill/finish market, highlighted by Novo Nordisk's acquisition of three fill/finish sites from Catalent.
Why It's Important?
The expansion of PCI Pharma Services' capabilities is crucial in addressing the growing demand for sterile fill/finish services in the pharmaceutical industry. This move positions PCI to better serve its clients, including major biotech firms like Horizon Therapeutics and Zogenix, which have outsourced work to PCI. The investment also reflects a strategic response to market disruptions, such as those caused by quality issues at other fill/finish facilities. By enhancing its infrastructure, PCI aims to secure its position as a leading contract development and manufacturing organization (CDMO) in the U.S., potentially increasing its market share and competitiveness in the global pharmaceutical supply chain.
What's Next?
PCI plans to continue its expansion by adding autoinjector and drug-device combination assembly infrastructure at its Philadelphia and Rockford, Illinois sites. This phased approach will increase PCI's U.S. autoinjector and device assembly capacity to over 250 million units per year by 2027. The company is also likely to explore further strategic partnerships and investments to support its growth and meet the increasing demand for its services. Stakeholders in the pharmaceutical industry will be closely monitoring PCI's progress and its impact on the fill/finish market.
